Comparative Pharmacology
Head-to-head clinical analysis: ADPHEN versus MELFIAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADPHEN versus MELFIAT.
ADPHEN vs MELFIAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adphen is a combination of phentermine hydrochloride and diethylpropion hydrochloride. Phentermine is a sympathomimetic amine that acts as an appetite suppressant by stimulating the hypothalamus to release norepinephrine, thereby reducing food intake. Diethylpropion also has sympathomimetic activity, though its exact mechanism is not fully understood.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
5 mg orally once daily, titrated to a maximum of 10 mg once daily as tolerated.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
None Documented
None Documented
Terminal elimination half-life is 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
Primarily renal (70-90% as unchanged drug) with minor biliary (10-15% as metabolites). Fecal elimination is negligible (<5%).
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Category C
Category C
Anorexiant
Anorexiant